دورية أكاديمية
أعرض في EDS

Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In locally advanced HER2-positive breast cancer: a prospective cohort study with propensity-matched analysis.

التفاصيل البيبلوغرافية
العنوان: Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In locally advanced HER2-positive breast cancer: a prospective cohort study with propensity-matched analysis.
المؤلفون: Jiang M; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Chai Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Liu J; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., He M; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Wang Y; Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Yang X; Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Xing Z; Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Zhang M; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Zhou S; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Ma F; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Wang J; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Yuan P; Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Xu B; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. xubinghebm@163.com., Li Q; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. liqiao@cicams.ac.cn.
المصدر: BMC cancer [BMC Cancer] 2024 Jul 22; Vol. 24 (1), pp. 877. Date of Electronic Publication: 2024 Jul 22.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2001-
مواضيع طبية MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Breast Neoplasms*/metabolism , Carboplatin*/administration & dosage , Carboplatin*/therapeutic use , Neoadjuvant Therapy*/methods , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Receptor, ErbB-2*/metabolism , Propensity Score* , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage , Taxoids*/administration & dosage , Taxoids*/therapeutic use, Humans ; Female ; Middle Aged ; Prospective Studies ; Adult ; Aged ; Trastuzumab/therapeutic use ; Trastuzumab/administration & dosage ; Treatment Outcome
مستخلص: Background: Inetetamab is the first domestically developed innovative anti-HER2 monoclonal antibody in China, proven effective and safe in HER2-positive advanced breast cancer. However, its efficacy and safety in neoadjuvant treatment of HER2-positive locally advanced breast cancer (LABC) remain to be validated.
Methods: This prospective cohort study aimed to evaluate the efficacy and safety of inetetamab combined with pertuzumab, taxanes, and carboplatin (TCbIP) in neoadjuvant therapy for HER2-positive LABC, comparing it to data from patients treated with the TCbHP regimen (trastuzumab combined with pertuzumab, taxanes, and carboplatin) using propensity score matching (PSM). The primary endpoint was total pathological complete response (tpCR). Adverse events (AEs), objective response rate (ORR), and near-pCR were key secondary endpoints.
Results: Forty-four patients with clinical stage IIA-IIIC HER2-positive LABC were prospectively enrolled and treated with the TCbIP regimen. The tpCR rate among 28 patients who completed surgery was 60.7%, comparable to and slightly higher than the TCbHP group in PSM (60.7% vs. 53.6%, P = 0.510). The ORR was 96.4%, and the DCR reached 100.0%. The most common ≥ grade 3 AE was neutropenia (21.4% vs. 11.9%, P = 0.350). No significant reduction in left ventricular ejection fraction was observed, and no patient withdrew from treatment due to AEs.
Conclusion: Neoadjuvant therapy with TCbIP showed good efficacy and safety in patients with HER2-positive LABC and might be another promising option for neoadjuvant treatment.
Trial Registration: NCT05749016 (registration date: Nov 01, 2021).
(© 2024. The Author(s).)
References: Open Life Sci. 2023 Jan 10;18(1):20220535. (PMID: 36694697)
J Clin Oncol. 2023 Jun 1;41(16):2998-3008. (PMID: 37075276)
Front Oncol. 2022 Oct 06;12:1019925. (PMID: 36276123)
Cancer Treat Rev. 2023 Feb;113:102500. (PMID: 36587473)
Cancer Treat Rev. 2021 Jul;98:102222. (PMID: 34023642)
Ann Oncol. 2013 Dec;24(12):2990-4. (PMID: 24013581)
Lancet. 2021 May 8;397(10286):1750-1769. (PMID: 33812473)
N Engl J Med. 2019 Feb 14;380(7):617-628. (PMID: 30516102)
Lancet Oncol. 2018 Dec;19(12):1630-1640. (PMID: 30413379)
Int J Mol Sci. 2022 Feb 18;23(4):. (PMID: 35216405)
Breast. 2015 Nov;24 Suppl 2:S44-8. (PMID: 26321480)
Nat Rev Drug Discov. 2023 Feb;22(2):101-126. (PMID: 36344672)
Curr Cancer Drug Targets. 2024;24(5):490-500. (PMID: 37916639)
Front Immunol. 2022 Jun 30;13:919369. (PMID: 35844533)
Lancet Oncol. 2018 Jan;19(1):115-126. (PMID: 29175149)
Front Oncol. 2023 Jun 19;13:1136380. (PMID: 37404769)
Zhonghua Yi Xue Za Zhi. 2020 Aug 11;100(30):2351-2357. (PMID: 32791810)
Ann Oncol. 2013 Sep;24(9):2278-84. (PMID: 23704196)
Clin Cancer Res. 2023 Apr 14;29(8):1569-1581. (PMID: 36730339)
Eur J Cancer. 2023 Sep;190:112885. (PMID: 37142539)
Lancet Oncol. 2017 Dec;18(12):1688-1700. (PMID: 29146401)
Am J Transl Res. 2019 Sep 15;11(9):6110-6116. (PMID: 31632579)
Lancet Oncol. 2016 Jun;17(6):791-800. (PMID: 27179402)
Lancet Oncol. 2012 Jan;13(1):25-32. (PMID: 22153890)
J Natl Compr Canc Netw. 2022 Jun;20(6):723-734. (PMID: 35714678)
Semin Cancer Biol. 2021 Jul;72:123-135. (PMID: 32112814)
JAMA Oncol. 2020 Mar 1;6(3):e193692. (PMID: 31647503)
Cancer Pathog Ther. 2023 Oct 30;2(1):31-37. (PMID: 38328709)
Int J Biol Sci. 2023 Aug 6;19(13):4061-4081. (PMID: 37705753)
Cancers (Basel). 2023 Mar 26;15(7):. (PMID: 37046648)
Clin Cancer Res. 2020 Jun 15;26(12):2838-2848. (PMID: 32046998)
Lancet. 2014 Jul 12;384(9938):164-72. (PMID: 24529560)
Cancer Med. 2023 May;12(9):10526-10535. (PMID: 36934442)
فهرسة مساهمة: Keywords: HER2-positive breast cancer; Inetetamab; Neoadjuvant; Trastuzumab; pCR
سلسلة جزيئية: ClinicalTrials.gov NCT05749016
المشرفين على المادة: BG3F62OND5 (Carboplatin)
K16AIQ8CTM (pertuzumab)
EC 2.7.10.1 (Receptor, ErbB-2)
0 (Antibodies, Monoclonal, Humanized)
0 (Taxoids)
EC 2.7.10.1 (ERBB2 protein, human)
P188ANX8CK (Trastuzumab)
تواريخ الأحداث: Date Created: 20240722 Date Completed: 20240723 Latest Revision: 20240725
رمز التحديث: 20240726
مُعرف محوري في PubMed: PMC11265051
DOI: 10.1186/s12885-024-12654-3
PMID: 39039516
قاعدة البيانات: MEDLINE
الوصف
تدمد:1471-2407
DOI:10.1186/s12885-024-12654-3